An observational study in Primary Ciliary Dyskinesia and Kartagener Syndrome, sponsored by University of Bern. Recruiting at 1 site in Switzerland. Per ClinicalTrials.gov, last updated 2025-11-25.
Sponsored by University of Bern · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The Swiss Primary Ciliary Dyskinesia (PCD) Registry is a national patient registry that collects information on diagnosis, symptoms, treatment and follow-up of patients with PCD in Switzerland and provides data for national and international monitoring and research.
The Swiss Primary Ciliary Dyskinesia registry (CH-PCD) was founded in 2013 as a collaborative project between epidemiologists and adult and paediatric pulmonologists. It started as a pilot project in the canton of Bern and in 2014 was extended to include all Switzerland. The data centre of the SPCDR is located at the Institute of Social and Preventive Medicine at the University of Bern. It contributes data to the international PCD registry and other international studies such as the international PCD (iPCD) cohort.
Objectives of the CH-PCD:
The Swiss Primary Ciliary Dyskinesia Registry collects information on diagnosis, symptoms, treatment and follow-up of patients with PCD in Switzerland and provides data for national and international monitoring and research. In particular, it aims to:
Study design:
The CH-PCD is a patient registry. At baseline (inclusion of a patient to the registry), it collects retrospectively all available data since birth and it follows included patients throughout life until death or loss to follow up, collecting prospectively data at regular time intervals.
What data is collected:
The CH-PCD collects information on demographic characteristics (e.g. age, sex), diagnostic tests and clinical data about manifestations and management of the disease. It collects repeated follow-up data on growth, lung function, clinical manifestations from all affected organ systems, microbiology and imaging, lab results, therapeutic interventions (including surgery and physiotherapy) and hospitalisations. It also collects information on neonatal symptoms related to the disease and on the symptoms, that led to referral and PCD diagnosis.
Since 2020, the CH-PCD collects through questionnaire surveys patient-reported information on symptoms and lifestyle behaviours.
Study database:
The study database is web-based, using the Research Electronic Data Capture (REDCap) platform developed at Vanderbilt University. REDCap is widely used in academic research and allows data entry and extraction in various formats.
How to participate:
Patients with PCD who would like to participate to the registry as well as physicians who treat patients with PCD should contact the CH-PCD to receive the study information and informed consent forms.
For further details, please contact: spcdr@hin.ch
Funding:
The setting up of the CH-PCD (salaries, consumables and equipment) was funded by several Swiss funding bodies, including the Lung Leagues of Bern, St. Gallen, Vaud, Ticino and Valais and the Kantonalbernischer Hilfsbund.Research activities based on data included in the CH-PCD are funded by the Swiss National Science foundation (SNF 320030_173044, 320030B_192804 and PZ00P3_185923). The CH-PCD participated to the EU funded BEAT-PCD COST Action (BM1407) and participates to the BEAT-PCD clinical research collaboration supported by the European Respiratory Society.
21 studies on the registry are indexed under Kartagener Syndrome; 4 are open to participants now.
This study's planned enrollment of 800 is above the median of 200 across 17 observational studies indexed under Kartagener Syndrome.
Browse Kartagener Syndrome studies →University of Bern is the lead sponsor of 209 studies on the registry; 46 are open to participants now.
Compared within Kartagener Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Ciliary Motility Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Patients of all ages diagnosed with PCD, who are resident or treated in Switzerland.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Height
Height z-scores calculated based on available national and international references
Time frame: every 3 months up to 80 years
BMI
Body Mass Index (BMI) z-scores calculated based on available national and international references
Time frame: every 3 months up to 80 years
Lung function measurements
Spirometric indices, particularly Forced expiratory volume in 1 sec (FEV1) and Forced vital capacity (FVC) z-scores calculated based on Global Lung Function Initiative (GLI) reference values
Time frame: every 3 months up to 80 years
Measurement of nasal nitric oxide using breath analyzer
Results of nasal nitric oxide measurement, performed for diagnosis
Time frame: at study entry (in case patient is <5 years old at study entry, then the outcome will be assessed at age 5
Cilia ultrastructure identified using electron microscopy analysis
Results of electron microscopy analysis of cilia, performed for diagnosis
Time frame: at study entry
Ciliary beat frequency and beat pattern using video microscopy analysis
Results of video microscopy analysis of cilia, performed for diagnosis
Time frame: at study entry
Microbiological culture of respiratory samples
Results of microbiology cultures of respiratory samples (sputum, cough swabs, throat swabs, ear swabs, bronchoalveolar lavage) expressed in a qualitative (growth or no growth of pathogens) or semiquantitative way (the type of sample depends on the age of the patient and the clinic the sample was collected).
Time frame: every 3 months up to 80 years
Antibiotic resistance of microbes isolated in microbiological cultures
Information on antibiotic resistance of microbes isolated in microbiological cultures (see outcome 7) of respiratory samples, expressed either semiquantitatively or by the value of minimum inhibitory concentration.
Time frame: every 3 months up to 80 years
Chest computed tomography
Radiological findings from chest computed tomography
Time frame: every 3 months up to 80 years
Sinus computed tomography
Radiological findings from sinus computed tomography
Time frame: every 3 months up to 80 years
Vital status
Vital status of patient: has the patient died or is he/she still alive and in case of death what was the cause?
Time frame: every 3 months up to 80 years
Clinical symptoms frequency
Frequency of respiratory symptoms recorded with a patient or parent-reported questionnaire
Time frame: once a year up to 80 years
Plan to share: Undecided — Anonymised data are shared for international collaborative projects. For requests related to IPD please contact spcdr@hin.ch
Started Jan 2013 (actual). Primary completion is estimated for Dec 2080, 815 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.